TAB 8C

IN THE UNITED STATES DISTRICT COURT
FOR THE SOUTHERN DISTRICT OF WEST VIRGINIA
AT CHARLESTON

THE CITY OF HUNTINGTON, : Civil Action

Plaintiff, : No. 3:17-cv-01362

V.

AMERISOURCEBERGEN DRUG CORPORATION, et al.,

Defendants. :

CABELL COUNTY COMMISSION, : Civil Action

Plaintiff, : No. 3:17-cv-01665

v. :

AMERISOURCEBERGEN DRUG : CORPORATION, et al., :

Defendants. : x

BENCH TRIAL - VOLUME 8

BEFORE THE HONORABLE DAVID A. FABER, SENIOR STATUS JUDGE
UNITED STATES DISTRICT COURT
IN CHARLESTON, WEST VIRGINIA

MAY 12, 2021

```
1
            And if it's just 10,000, can you give us a rough
2
       estimate?
 3
            If it's just 10,000 -- well, one percent would be 100.
 4
       And, so, it would be fifteen hundredths of a percent.
 5
       Q.
            Okay.
 6
            So .15 percent.
 7
           Thank you, Dr. McCann. That's all I have for right
       Q.
 8
       now. I appreciate your time.
 9
                 THE COURT: Ms. Salgado.
10
                 MS. SALGADO: One minute, please, as we switch our
11
       technical.
12
                 THE COURT: Yes.
13
            (Pause)
14
                             CROSS EXAMINATION
15
       BY MS. SALGADO:
16
          Good morning, Dr. McCann.
17
           Good morning.
18
            Thanks for your patience over these last few days. I'm
19
       Suzanne Salgado. I represent Cardinal Health and I'll ask
20
       you just a few more questions.
21
       Α.
            Thank you.
22
            Dr. McCann, as part of your work as an expert in this
23
       case, you prepared tables that reflect your analysis of the
24
       market share of each of the wholesale distributors in Cabell
25
       County and the City of Huntington. Is that right?
```

Ayme A. Cochran, RMR, CRR (304) 347-3128

- 1 A. I don't know if I would describe it as analysis, but calculations of the market shares. Again, they're really

subtotals of the data, and we do that for the distributors

- 4 for various jurisdictions including Cabell County and the
- 5 City of Huntington.

- 6 Q. Okay. I'm going to show you one of those charts and
- 7 those set of calculations. It's from your Appendix 9-I and
- 8 it's Page 25 of that that I'll bring up here. But let me
- 9 know if you'd like a hard copy and we can provide you with
- 10 that as well.
- 11 A. Thank you.
- 12 Q. Now, this table presents your analysis -- or excuse
- me -- your calculations, subtotals of some of the data
- 14 regarding total dosage units of oxycodone and hydrocodone
- shipped by all distributors to all dispensers in
- 16 | Cabell/Huntington from 2006 to 2014; correct?
- 17 A. Correct.
- 18 Q. And that analysis, as you said, is based on ARCOS data;
- 19 | right?
- 20 A. Yes. It might be supplemented a little bit with
- 21 defendant transaction data, but the primary source is the
- 22 ARCOS data.
- 23 Q. Now, according to your analysis of the ARCOS data and
- 24 any supplementation you may have done, from 2006 to 2014
- 25 | Cardinal Health distributed 17 percent of the oxycodone and

1 hydrocodone shipped to Cabell and Huntington; correct? 2 Α. Correct. 3 And it's your understanding that Cardinal Health reported those transactions to the DEA in the ARCOS $\,$ 4 5 database; correct? 6 Α. Correct. 7 So Cardinal Health knew about the 17 percent of the 8 oxycodone and hydrocodone prescription opioids that were 9 shipped into Cabell and Huntington during that time frame; 10 correct? 11 Α. Yes. 12 And as far as you know, -- and the DEA -- excuse me --13 on the other hand knew about all of the oxycodone and 14 hydrocodone prescription opioids shipped into 15 Cabell/Huntington during that time frame; correct? 16 Α. Correct. 17 And I think we discussed this a little bit yesterday, 18 but as far as you're aware, at least before 2018, other than 19 the data on the volume -- or excuse me -- other than 20 Cardinal Health's own shipments, a distributor would not 21 have had access to the data that other wholesale 22 distributors reported to ARCOS; correct? 23 I'll rephrase. You're not aware of Cardinal Health 24 having access to the data of other distributors during this 25 time frame; correct?

Ayme A. Cochran, RMR, CRR (304) 347-3128

A. Correct.

- 2 Q. Dr. McCann, yesterday you were referring to some
- 3 tables -- or excuse me -- a table showing the pharmacies in
- 4 Cabell and Huntington that received shipments of oxycodone
- and hydrocodone between 2006 and 2014. And I want to go
- 6 through one of those.
- 7 If we could please pull up P-44752 and go to the second
- 8 page of that document.
- 9 I'd like to focus in particular on A-Plus Care Pharmacy
- 10 listed here. According to your chart, how many dosage units
- of oxycodone and hydrocodone were shipped to A-Plus Care
- 12 Pharmacy?
- 13 **A.** 583,000.
- 14 Q. And how many MMEs of oxycodone and hydrocodone were
- shipped to A-Plus Care Pharmacy according to your chart?
- 16 **A.** 17,365,587.
- 17 Q. And A-Plus Care Pharmacy is listed here because it is
- in Cabell, right, or it was in Cabell?
- 19 A. Correct.
- 20 Q. But you didn't testify about which distributor sold
- 21 oxycodone and hydrocodone to A-Plus Care Pharmacy during
- 22 Mr. Mougey's questioning of you; right?
- 23 A. I don't recall discussing this pharmacy.
- 24 Q. Let me show you a table that you prepared as part of
- your expert materials before you came to testify. In

- 1 Q. Would you agree with me that this chart shows that the
- 2 DEA aggregate production quota for oxycodone in 2010 was at
- 3 least ten times greater than it was in 1997?
- 4 **A.** Yes.
- 5 Q. You testified about several other charts that showed
- distributions of oxycodone and hydrocodone by all
- 7 distributors to all dispensers from 1997 to 2019; do you
- 8 recall that?
- 9 **A.** Yes.
- 10 Q. Let's pull up Plaintiffs' 44711, Page 4, please. This
- is one of your charts and it represents shipments of
- 12 oxycodone and hydrocodone reflected in the ARCOS Retail Drug
- Summary Reports converted by you into MMEs for the entire
- 14 United States, correct?
- 15 A. Correct.
- 16 O. You've testified that this chart showed that from 1997
- 17 to 2010 the volume of oxycodone and hydrocodone for the
- 18 entire United States increased by approximately ten or
- 19 eleven-fold; do you recall that?
- 20 **A.** Yes.
- 21 Q. Let's pull up Plaintiffs' Exhibit 44711, Page 8,
- 22 please. This chart represents shipments of oxycodone and
- 23 hydrocodone also reflected in the ARCOS Retail Drug Summary
- Reports and converted by you into MMEs for the entire State
- of West Virginia; is that right?

A. Yes.

- 2 Q. You testified that this chart shows that from 1997 to
- 3 2010 the volume of oxycodone and hydrocodone shipped to the
- 4 entire State of West Virginia increased also by
- 5 approximately ten or eleven-fold; do you recall that?
- 6 **A.** Yes.
- 7 Q. So, the magnitude of the increase was approximately the
- 8 | same for the State of West Virginia as it was for the United
- 9 States as a whole, correct?
- 10 **A.** Yes.
- 11 Q. Let's pull up P-44711, Page 11, please. This chart
- represents shipments of oxycodone and hydrocodone also
- reflected in the ARCOS Retail Drug Summary Reports and
- 14 | converted by you into MMEs for the three-digit zip codes in
- 15 West Virginia that encompass Cabell and Huntington, correct?
- 16 **A.** Yes.
- 17 Q. And you testified that this chart shows that from 1997
- 18 | to 2010 the volume of oxycodone and hydrocodone shipped to
- 19 | the three-digit zip codes that encompass Cabell and
- 20 Huntington also increased by approximately ten-fold; do you
- 21 recall that?
- 22 **A.** Yes.
- 23 Q. So, the magnitude of the increase was approximately the
- same in Cabell-Huntington as it was for the State of West
- 25 Virginia, as well as the United States as a whole, correct?

- 1 A. Correct.
- 2 Q. So, across the DEA oxycodone quota and your analysis of
- 3 total distributions of oxycodone and hydrocodone to the
- 4 United States, West Virginia, and Cabell, and Huntington,
- 5 the trend is the same, we see about a ten-fold increase; do
- 6 you agree?
- 7 **A.** Yes.
- 8 Q. If we could pull up the demonstrative putting those
- 9 | side-by-side. So, that's why when you look at these charts
- 10 together, you see the similar upward slope from 1997 to
- 11 | 2010, correct?
- 12 A. I'm sorry. What do you mean by "that's why"?
- 13 Q. Because it's a similar factor, because it's the same
- 14 | factor of ten, we see a similar trend across all of these
- 15 graphs, correct?
- 16 A. I'm sorry. Yes. The -- the graphs all reflect a
- 17 roughly ten-fold increase and so, visually, they appear to
- 18 have the same slope.
- 19 Q. Okay. Now, you created these -- the charts that you
- 20 made, the ones that the orange and blue lines, using
- 21 publicly available information from the ARCOS Retail Drug
- 22 Summary Reports, correct?
- 23 **A.** Yes.
- 24 Q. And you accessed those reports on-line?
- 25 **A.** Yes.

- 1 Those Retail Drug Summary Reports reflect distributions Ο. 2 to each state broken up by three digit zip code within that 3 state year by year and quarter by quarter, right? 4 Correct. 5 And you testified that those Retail Drug Summary 6 Reports, which date back to 1997, have been publicly 7 available for many years, potentially as early as 1998, 8 correct?
- 9 A. Correct.
- Q. So, individuals in Cabell and Huntington, law
 enforcement, public health officials, City Council members,
 Cabell County Commissioners, could have access to this
 publicly available information of quarterly shipments to the
 and Huntington, law
 enforcement, public health officials, City Council members,
 cabell County Commissioners, could have access to this
 publicly available information of quarterly shipments to the
 - A. I don't know one way or another, but I don't know any reason why not.
- 17 Q. You don't know any reason why not, right?
- 18 A. Correct.

15

16

19 Q. You can take that back down. Thank you.

Many of the charts and graphs you testified about with

Mr. Mougey reflect your calculation of how many prescription

opioids were shipped to jurisdictions on a per capita basis;

do you recall that?

- 24 **A.** Yes.
- 25 Q. So, let's discuss briefly the per capita calculations

1 Α. Yes. 2 And for other of the distribution centers, you didn't 3 provide the names or locations, but you did provide the 4 unique DEA registration number, correct? 5 Correct. 6 And each of those numbers corresponds to an 7 identifiable distribution center, right? 8 Correct. 9 And you may not have identified it, but it would be 10 possible to be identified, correct? 11 Correct. I'm not sure why the city and state is not on 12 this for those two or three -- three that just have the DEA 13 number. 14 Q. Okay. So --15 THE COURT: Excuse me. Dr. McCann, did the 16 documentation that was furnished to you include the 17 shipments to every pharmacy by these three defendants in 18 West Virginia, for example? 19 THE WITNESS: Yes, Your Honor. 20 BY MS. SALGADO: 21 On this chart, if none of these -- assuming none of 22 these DEA registration numbers corresponds to Cardinal 23 Health's distribution center in Lakeland, Florida, then that

distribution center in Lakeland didn't ship any hydrocodone

means, according to your analysis, the Cardinal Health

24

```
1
       or oxycodone to Cabell-Huntington, correct?
 2
                 THE COURT: I'm sorry to interrupt again.
 3
                              That's okay.
                 MS. SALGADO:
 4
                 THE COURT: I didn't ask the precise question I
 5
       wanted you to answer. I asked you if the data included the
 6
       shipments of every pharmacy. What I meant to ask was did it
 7
       show the specific shipments to each specific pharmacy?
                 THE WITNESS: Oh, yes. The data is -- if you
 8
 9
       visualized it, it would be millions of lines of data, each
10
       line showing a specific shipment of a specific drug package
11
       from -- from a distributor and identifying which
12
       distribution facility it came from to a specific pharmacy.
13
       It will give the pharmacy's DEA number and the physical
14
       location of the pharmacy, as well as the name and some other
15
       information, but that's for every single shipment into
16
       Cabell County and the City of Huntington.
17
                 THE COURT: Okay. I'm sorry to interrupt you.
18
                 MS. SALGADO: That's okay. No problem.
19
                 BY MS. SALGADO:
20
            Just back on this, Dr. McCann, I believe you answered
21
       this, but making sure we're clear, that if none of the DEA
22
       registration numbers on this chart corresponds to Cardinal
23
       Health's Lakeland, Florida distribution center, then that
       means, according to your analysis, the Cardinal Health
24
25
       Lakeland Distribution Center did not ship any oxycodone or
```

- 1 | hydrocodone into Cabell-Huntington, correct?
- 2 A. At least not directly into Cabell County and the City
- 3 of Huntington.
- 4 Q. And the same is true for Cardinal Health's Auburn,
- 5 Washington facility?
- 6 A. Yes. Same answer, not directly, at least into Cabell
- 7 | County and the City of Huntington.
- 8 Q. And the same is true for Cardinal Health's Swedesboro,
- 9 New Jersey Distribution Center?
- 10 A. Correct.
- 11 Q. And the same is true for Cardinal Health's Stafford,
- 12 Texas Distribution Center, correct?
- 13 A. Correct.
- 14 Q. Dr. McCann, you're not aware of any shipment by any
- distributor in this courtroom to a pharmacy that was not
- 16 registered with the DEA and licensed by its state regulator,
- 17 correct?
- 18 A. Correct.
- 19 Q. And of all the distributor shipments that you've
- analyzed, you're not aware of a single shipment shipped to a
- 21 pharmacy without an order placed by that pharmacy for that
- 22 shipment, correct?
- 23 A. Correct.
- MS. SALGADO: That's all I have. Thank you so
- 25 much.